Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase

https://doi.org/10.1016/0952-3278(92)90098-4Get rights and content

Abstract

The studies described herein were undertaken with the objective of determing the effect of modulation of arachidonic acid metabolism on proliferation of rat mammary tumor cells in culture. The TMT-081 rat mammary tumor cell line was shown to metabolize [14C]arachidonic acid to thromboxane B2, PGE2, PGF, and 12- and/or 15-HETE. Furthermore, synthesis of these eicosanoids was physiologically significant since each metabolite stimulated DNA synthesis. Both cyclooxygenase and lipoxygenase inhibitors suppressed cell growth and modulated eicosanoid synthesis in a concentration-dependent manner. Thin layer chromatography showed that the production of cyclooxygenase metabolites (thromboxane B2, PGE2 and PGF) by TMT-081 cells was inhibited by indomethacin, ibuprofen, BW755C and timegadine. The lipoxygenase inhibitor NDGA was also shown to inhibit thromboxane B2 synthesis, but increased PGE2 and PGF syntheses; esculetin, a lipoxygenase inhibitor in other systems, increased all the cyclooxygenase products. The production of the lipoxygenase products 12- and/or 15-HETE was inhibited by NDGA, increased by indomethacin and ibuprofen, but not affected by esculetin, BW755C and timegadine in this cell line. Changes in eicosanoid profile were observed before drug-induced inhibition of cell growth suggesting that the balance of the various eicosanoids may be a critical determinant of cell proliferation. However, since drug-induced effects on arachidonic acid profile occurred at concentrations lower than that necessary for inhibition of cell growth, the effects of these inhibitors on other biochemical pathways affecting cell growth cannot be ruled out.

References (45)

  • GK Bandyopadhyay et al.

    Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor

    J. Biol. Chem.

    (1987)
  • AS Gukovskaya et al.

    Inhibitors of arachidonic acid metabolism eliminate the increase in cytosolic free calcium induced by the mitogen concanavalin A in rat thymocytes

    FEBS Letters

    (1989)
  • JY Vanderhoek et al.

    Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leukocytes by the anti-inflammatory agent ibuprofen

    J. Biol Chem.

    (1984)
  • FA Kuehl et al.

    Interactions between prostaglandins and leukotrienes

    Biochem. Pharmacol.

    (1984)
  • RF Myers et al.

    Differential effects of anti-inflammatory drugs on lipoxygenase and cyclooxygenase activities of neutrophils from a reverse passive arthus reaction

    Biochem. Biophys. Res. Commun.

    (1983)
  • J Chang et al.

    Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages

    Eur. J. Pharmacol.

    (1985)
  • BNY Setty et al.

    The mitogenic effect of 15- and 12-hydroxyeicosatetraenoic acid on endothelial cells may be mediated via diacylglycerol kinase inhibition

    J. Biol. Chem.

    (1987)
  • KV Honn et al.

    Prostaglandins and cancer: a review of tumor initiation through tumor metastases

    Prostaglandins

    (1981)
  • GK Bandyopadhyay et al.

    Proliferative effects of insulin and epidermal growth factor on mouse mammary epithelial cells in primary culture

    J. Biol. Chem.

    (1988)
  • IB Verogote et al.

    Prostaglandin F in benign and malignant breast tumors

    Br. J. Cancer

    (1985)
  • CW Welsch et al.

    Enhancement of murine mammary tumorigenesis by feeding high levels of dietary fat: a hormonal mechanism?

    J. Nat. Cancer Inst.

    (1983)
  • CA Carter et al.

    Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat

    Cancer Res.

    (1983)
  • Cited by (64)

    • Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial

      2011, Journal of Steroid Biochemistry and Molecular Biology
      Citation Excerpt :

      The therapeutic possibilities of COX-2 inhibition has been investigated since epidemiological studies suggested the inverse association between regular intake of nonsteroidal anti-inflammatory drugs (NSAIDs) and the breast cancer risk [31–33]. COX-2 inhibitors were found to be able to inhibit the carcinogenesis of mammary tumors in rodent models [34–37]. Celecoxib (CXB), a promising selective COX-2 inhibitor, demonstrated its chemopreventive ability in rodent models with breast cancer.

    View all citing articles on Scopus
    View full text